The potent platelet glycoprotein IIb/IIIa antagonist, roxifiban, is produced in crystalline form. Crystalline roxifiban exists in two polymorphic forms, designated Form 1 and Form 2. These polymorphic forms are characterized by xray powder diffraction and solid-state carbon NMR. Pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation are described.
申请公布号
CA2294047(A1)
申请公布日期
1998.12.23
申请号
CA19982294047
申请日期
1998.06.12
申请人
DUPONT PHARMACEUTICALS COMPANY
发明人
MELONI, DAVID J.;MAURIN, MICHAEL B.;MA, PHILIP;ROSSANO, LUCIUS T.;ZHANG, LIN-HUA;PESTI, JAAN A.;WARD, RANDALL K.;YIN, JIANGUO
